CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2010-11-02): Vitamin E improves liver histology in pediatric NAFLD


Vitamin E improves liver histology in pediatric NAFLD

Last Updated: 2010-11-02 17:40:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Children with nonalcoholic fatty liver disease (NAFLD) who took vitamin E had significant improvements in their liver histology, researchers said this week at the annual meeting of the American Association for the Study of Liver Diseases in Boston.

The children were enrolled in a 96-week randomized trial comparing the effects of vitamin E, metformin, and placebo on a variety of endpoints. Neither intervention achieved the primary goal - a reduction in serum alanine aminotransferase (ALT) levels throughout weeks 48 to 96 to below 40 IU/L or <50% of baseline

However, kids in the vitamin E arm had greater improvements in hepatocellular ballooning than those on placebo (mean score change of -0.5 vs. 0.1, P=0.006) and mean NAFLD activity score (-1.8 vs. -0.7, P=0.02).

Among the children who had nonalcoholic steatohepatitis (NASH) at the study's outset, 25 of 43 (58%) in the vitamin E group had resolution by week 96, compared to 11 of 39 (28%) in the placebo group (P=0.006).

Metformin had no effect on any of those features - and neither vitamin E nor metformin was better than placebo for improving fibrosis, lobular inflammation, or portal inflammation scores.

Right now, treatment for NAFLD and NASH in children consists of "lifestyle advice about diet and exercise," said Dr. Joel E. Lavine of Columbia University in New York City, the study's first author. Based on the new findings, he told Reuters Health, pediatric NALFD patients who have biopsies showing ballooning and ALT levels above 60 IU/L could benefit from adding vitamin E to standard-of-care lifestyle advice.

At the outset, Dr. Lavine and colleagues from 10 centers randomly assigned 173 children ages 8 to 17 years, all with ALT above 60 U/L and biopsy-confirmed NAFLD, to take either 400 IU of vitamin E twice a day (58 patients), 500 mg of metformin twice daily (57 patients), or placebo (58 patients) for 96 weeks.

"This is the first pediatric trial for any liver disease, ever, that used histology as a predesignated endpoint," Dr. Lavine noted. "It also showed the feasibility of being able to do it effectively. Eighty-five percent of the children that were randomized completed the course of treatment and underwent a research liver biopsy."

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2017 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.